• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.23% Nasdaq Down0.63%

    Vical Incorporated (VICL)

    0.96 Down 0.05(4.48%) 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Vical Incorporated
    10390 Pacific Center Court
    San Diego, CA 92121
    United States - Map
    Phone: 858-646-1100
    Fax: 858-646-1150
    Website: http://www.vical.com

    Index Membership:N/A
    Full Time Employees:68

    Business Summary 

    Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Vical Incorporated

    Corporate Governance 
    Vical Incorporated’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 10; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Vijay B. Samant , 62
    Chief Exec. Officer, Pres, Acting Chief Financial Officer and Director
    Mr. Anthony Alan Ramos , 48
    Chief Accounting Officer and VP of Fin.
    Dr. Igor P. Bilinsky Ph.D., 42
    Sr. VP of Corp. Devel.
    Dr. Lawrence Russell Smith Ph.D., 54
    VP of Vaccine Research
    Dr. Mammen P. Mammen Jr., M.D., 51
    VP of Clinical Vaccines
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders